It's only been two weeks since Pfizer closed its $6.7 billion takeover of Arena Pharmaceuticals, and it already has the positive data it was hoping for with etrasimod, the main asset in the deal.

Etrasimod, a next-generation, once-daily selective sphingosine-1-phosphate (S1P) receptor modulator, is being developed for the treatment of moderately to severely active ulcerative colitis (UC).

Pfizer placed a $6.7 billion bet on the outcome of two phase 3 trials of Arena Pharmaceuticals' etrasimod in ulcerative colitis (UC) when it acquired the company earlier this year, and the gamble ...

Data confirms significant clinical and endoscopic benefits of etrasimod 2mg after 40 weeks of maintenance treatment; Etrasimod demonstrates robust efficacy across multiple endpoin ...